HC Wainwright Raises I-Mab (NASDAQ:NBP) Price Target to $9.00

I-Mab (NASDAQ:NBP) had its price objective lifted by research analysts at HC Wainwright from $7.00 to $9.00 in a research note issued to investors on Friday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 143.24% from the stock’s previous close. HC Wainwright also issued estimates for I-Mab’s Q1 2026 earnings at ($0.07) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2030 earnings at $0.14 EPS.

I-Mab Stock Up 11.1%

NASDAQ:NBP opened at $3.70 on Friday. The firm has a market capitalization of $426.57 million, a PE ratio of -10.28 and a beta of 1.62. I-Mab has a one year low of $0.60 and a one year high of $6.79.

I-Mab (NASDAQ:NBP) last issued its quarterly earnings results on Thursday, December 18th. The company reported ($0.07) earnings per share (EPS) for the quarter.

About I-Mab

I-Mab is a clinical-stage biotechnology company focused on the discovery, development and commercialization of biologic therapies for oncology and immunology indications. The company concentrates on advancing antibody-based therapeutics and other protein biologics intended to modulate the immune system to treat cancer and autoimmune or inflammatory diseases. Its development activities span preclinical research through late-stage clinical trials, with an emphasis on creating targeted, differentiated molecules designed to address unmet medical needs.

Headquartered in China with global development activities, I-Mab operates research and development facilities and engages with clinical investigators and regulatory authorities across multiple geographies to support global clinical programs.